Table 3.
Independent predictors associated with new-onset fatty liver in the PSM cohorts
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| TOR use (versus TAM) | 0.58 (0.35–0.94) | 0.026 | 0.55 (0.33,0.91) | 0.020 |
| Age | 1.05 (1.01–1.09) | 0.008 | 1.03 (0.98,1.07) | 0.248 |
| BMI | 1.26 (1.16–1.37) | <.0001 | 1.23 (1.13,1.35) | <.0001 |
| ALT/AST ratio | 4.74 (1.59–14.11) | 0.005 | 3.93 (1.16,13.29) | 0.028 |
| HDL-cholesterol | 0.52 (0.25–1.08) | 0.079 | ||
| Triglyceride | 1.36 (1.06–1.75) | 0.016 | 1.27 (0.94,1.72) | 0.126 |
| Endocrine therapy duration | 0.99 (0.96–1.02) | 0.649 | ||
| Radiotherapy | 0.65 (0.39–1.09) | 0.106 | ||
| Chemotherapy | 1.18 (0.66–2.13) | 0.575 | ||
| Diabetes | 4.35 (1.06–17.88) | 0.041 | 4.16 (0.87,19.95) | 0.075 |
| Hypertension | 1.56 (0.74–3.26) | 0.241 | 0.97 (0.42,2.25) | 0.952 |
| Cancer stage (versus stage 0) | ||||
| 1 | 0.60 (0.26–1.37) | 0.225 | ||
| 2 | 2.05 (0.98–4.26) | 0.055 | ||
| 3 | 0.94 (0.36,2.45) | 0.906 | ||
Statistically significant values are highlighted in italics
Abbreviations: HR hazard ratio; CI confidence interval; TAM tamoxifen; TOR toremifene; BMI body mass index; ALT alanine aminotransferase; AST aspartate aminotransferase; HDL-C high-density lipoprotein-cholesterol